GlassScriptPhysician profile
Justin L Casey
NPI 1053549063
$8,931.29
in general payments reported to CMS, 2019-2025
41 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,056 · 2022: $2,005 · 2023: $1,837 · 2024: $1,846 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,869.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $840.37 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $767.58 | 2021-2025 | |
| Novo Nordisk INC | $728.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $692.57 | 2021-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $691.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $546.87 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $432.79 | 2021-2024 | |
| Pfizer INC. | $408.92 | 2021-2025 | |
| Gilead Sciences, INC. | $387.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $377.25 | 2021-2024 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $326.31 | 2021-2024 | Xarelto |
| Abbott Laboratories | $273.14 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $266.05 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $255.82 | 2021-2024 | Camzyos, Eliquis |
| Averitas Pharma INC. | $220.77 | 2023-2025 | Qutenza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.